Converge Bio: $25 Million Series A Raised To Expand Generative AI Drug Discovery Platform
By Amit Chowdhry ● Jan 13, 2026
Converge Bio, an AI platform focused on accelerating drug discovery and development, announced it has raised $25 million in Series A funding, bringing total capital raised to $30 million. The highly oversubscribed round was led by Bessemer Venture Partners, with participation from TLV Partners, Vintage Investment Partners, and Saras Capital, along with individual executives from Meta, OpenAI, and Wiz.